CAM
TSVT

Creekmur Asset Management’s 2seventy bio TSVT Stock Holding History

Creekmur Asset Management’s Portfolio TSVT Stock Details TSVT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-30
Closed -$116 – 1121
2024
Q2 		$116 Buy
+30
New +$135 ﹤0.01% 944

Other funds holding TSVT

KCM
Kynam Capital Management Princeton, New Jersey $1.62B AUM 138.67% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
MAP
Madison Avenue Partners New York $2.3B AUM 115.82% 1-Year Est. Return
NM
Newtyn Management New York $936M AUM 27.23% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
CC
Casdin Capital New York $1.32B AUM 76.62% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return

Creekmur Asset Management's TSVT Position: Q3 2024 in Review

Creekmur Asset Management sold out of 2seventy bio (TSVT) in Q3 2024, closing a stake of 30 shares — an estimated $116 sold.

Creekmur Asset Management first reported a position in TSVT in Q2 2024 and held it in 1 quarter. The position peaked at $116 in Q2 2024. 115 funds tracked by Wall St. Rank hold TSVT as of Q3 2024.

  • Creekmur Asset Management reported no remaining 2seventy bio position as of Q3 2024 after selling out during the quarter.
  • Creekmur Asset Management sold 30 2seventy bio shares in Q3 2024, an estimated $116.
  • Creekmur Asset Management first reported a position in 2seventy bio in Q2 2024 and held it in 1 quarter.
  • Creekmur Asset Management's 2seventy bio position peaked at $116 in Q2 2024.
  • 115 funds tracked by Wall St. Rank held 2seventy bio as of Q3 2024.

Based on Creekmur Asset Management's 13F filing for Q3 2024, filed 25 Oct 2024.